Patents by Inventor Benjamin P. Woolven
Benjamin P. Woolven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170210814Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: March 27, 2017Publication date: July 27, 2017Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9629909Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: June 18, 2013Date of Patent: April 25, 2017Assignee: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9028822Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.Type: GrantFiled: July 13, 2011Date of Patent: May 12, 2015Assignee: Domantis LimitedInventors: Neil D. Brewis, Benjamin P. Woolven, Steve Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein
-
Publication number: 20130309227Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: June 18, 2013Publication date: November 21, 2013Applicant: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8497244Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: January 23, 2012Date of Patent: July 30, 2013Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20130040383Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: August 14, 2012Publication date: February 14, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20130022605Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.Type: ApplicationFiled: July 13, 2011Publication date: January 24, 2013Inventors: Neil D. Brewis, Benjamin P. Woolven, Steven Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein
-
Patent number: 8263076Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF?, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: GrantFiled: January 18, 2011Date of Patent: September 11, 2012Assignee: Cephalon Australia Pty Ltd.Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20120114651Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8129503Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: October 23, 2006Date of Patent: March 6, 2012Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20110237780Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: January 18, 2011Publication date: September 29, 2011Applicant: Peptech LimitedInventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Patent number: 7981414Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: GrantFiled: December 20, 2006Date of Patent: July 19, 2011Assignee: Cephalon Australia Pty LtdInventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20110044979Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.Type: ApplicationFiled: July 7, 2010Publication date: February 24, 2011Inventors: Anthony G. DOYLE, Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Philip A. Jennings
-
Patent number: 7846439Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.Type: GrantFiled: February 1, 2007Date of Patent: December 7, 2010Assignee: Cephalon Australia Pty LtdInventors: Anthony G. Doyle, Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Philip A. Jennings
-
Publication number: 20100034831Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: October 23, 2006Publication date: February 11, 2010Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20090286962Abstract: The present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.Type: ApplicationFiled: December 20, 2006Publication date: November 19, 2009Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20090226428Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: December 20, 2006Publication date: September 10, 2009Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings